160 related articles for article (PubMed ID: 38465242)
1. CLINICAL VALIDATION OF ANKRD36 MUTATIONS AS A NOVEL BIOMARKER FOR MONITORING EARLY PROGRESSION AND TIMELY CLINICAL INTERVENTIONS IN BLAST CRISIS CML.
Absar M; Alanazi N; Siyal A; Shammas M; Mahmood A; Basit S; AlMukhaylid S; Iqbal Z
J Popul Ther Clin Pharmacol; 2022 Jun; 29(2):311-320. PubMed ID: 38465242
[TBL] [Abstract][Full Text] [Related]
2. Integrated Genomic Analysis Identifies ANKRD36 Gene as a Novel and Common Biomarker of Disease Progression in Chronic Myeloid Leukemia.
Iqbal Z; Absar M; Akhtar T; Aleem A; Jameel A; Basit S; Ullah A; Afzal S; Ramzan K; Rasool M; Karim S; Mirza Z; Iqbal M; AlMajed M; AlShehab B; AlMukhaylid S; AlMutairi N; Al-Anazi N; Sabar MF; Arshad M; Asif M; Shammas M; Mahmood A
Biology (Basel); 2021 Nov; 10(11):. PubMed ID: 34827175
[No Abstract] [Full Text] [Related]
3. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
[TBL] [Abstract][Full Text] [Related]
4. Whole exome sequencing identifies a novel FANCD2 gene splice site mutation associated with disease progression in chronic myeloid leukemia: Implication in targeted therapy of advanced phase CML.
Absar M; Mahmood A; Akhtar T; Basit S; Ramzan K; Jameel A; Afzal S; Ullah A; Qureshi K; Alanazi N; Iqbal Z
Pak J Pharm Sci; 2020 May; 33(3(Special)):1419-1426. PubMed ID: 33361032
[TBL] [Abstract][Full Text] [Related]
5. Targeted chronic myeloid leukemia therapy: seeking a cure.
Fausel C
J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
[TBL] [Abstract][Full Text] [Related]
6. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
[TBL] [Abstract][Full Text] [Related]
7. The proto-oncogene expression varies over the course of chronic myeloid leukemia.
Vidović A; Janković G; Colović M; Tomin D; Perunicić M; Bila J; Marković O; Bosković D
Hematology; 2008 Feb; 13(1):34-40. PubMed ID: 18534064
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
[TBL] [Abstract][Full Text] [Related]
9. Chronic Myeloid Leukemia: Part II-Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective.
Atallah EL; Maegawa R; Latremouille-Viau D; Rossi C; Guérin A
J Health Econ Outcomes Res; 2022; 9(2):30-36. PubMed ID: 35979529
[No Abstract] [Full Text] [Related]
10. [Research advance on molecular genetics of CML blast crisis].
Zhu HQ; Zhang S; Liu XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
[TBL] [Abstract][Full Text] [Related]
11. Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Iqbal Z; Absar M; Mahmood A; Aleem A; Iqbal M; Jameel A; Akhtar T; Karim S; Rasool M; Mirza Z; Khalid M; Akram AM; Sabar MF; Khalid AM; Aljarrah K; Iqbal J; Khalid M; Shah IH; Alanazi N
Asian Pac J Cancer Prev; 2020 Dec; 21(12):3517-3526. PubMed ID: 33369447
[TBL] [Abstract][Full Text] [Related]
12. BAX/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia.
Gonzalez MS; De Brasi CD; Bianchini M; Gargallo P; Moiraghi B; Bengió R; Larripa IB
Blood Cells Mol Dis; 2010 Oct; 45(3):192-6. PubMed ID: 20728382
[TBL] [Abstract][Full Text] [Related]
13. Sudden blast phase in pediatric chronic myeloid leukemia-chronic phase with abnormal lymphoid blasts detected by flow cytometry at diagnosis: Can it be considered a warning sign?
Vijayasekharan K; Chatterjee G; Ramanathan S; Narula G; Tembhare P; Subramanian PG; Patkar N; Gujral S; Shetty D; Banavali S
Cytometry B Clin Cytom; 2021 May; 100(3):345-351. PubMed ID: 33030302
[TBL] [Abstract][Full Text] [Related]
14. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
15. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
[TBL] [Abstract][Full Text] [Related]
16. Erythroid variant evolving from chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitors: a rare case report.
Lee MH; Song A; Li JY
Diagn Pathol; 2024 Jan; 19(1):21. PubMed ID: 38268039
[TBL] [Abstract][Full Text] [Related]
17. Characterization of cancer stem cells in chronic myeloid leukaemia.
Jørgensen HG; Holyoake TL
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
[TBL] [Abstract][Full Text] [Related]
18. Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
Etienne G; Dulucq S; Huguet F; Schmitt A; Lascaux A; Hayette S; Fort MP; Sujobert P; Bijou F; Morisset S; Tavitian S; Bidet A; Turcq B; Robbesyn F; Chollet C; Belloc F; Durrieu F; Mahon FX; Nicolini FE
Cancer Med; 2019 Sep; 8(11):5173-5182. PubMed ID: 31350815
[TBL] [Abstract][Full Text] [Related]
19. Diagnosing and managing advanced chronic myeloid leukemia.
Deininger MW
Am Soc Clin Oncol Educ Book; 2015; ():e381-8. PubMed ID: 25993200
[TBL] [Abstract][Full Text] [Related]
20. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients.
Marega M; Piazza RG; Pirola A; Redaelli S; Mogavero A; Iacobucci I; Meneghetti I; Parma M; Pogliani EM; Gambacorti-Passerini C
Leukemia; 2010 Aug; 24(8):1445-9. PubMed ID: 20520635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]